Erlotinib-loaded albumin nanoparticles: A novel injectable form of erlotinib and its in vivo efficacy against pancreatic adenocarcinoma ASPC-1 and PANC-1 cell lines.

Noorani, M; Azarpira, N; Karimian, K; Heli, H

Noorani, M; Azarpira, N; Karimian, K; Heli, H.

Afiliação

Noorani M; Department of Nanomedicine, School of Advanced Medical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran; Nanomedicine and Nanobiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Azarpira N; Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Karimian K; Arasto Pharmaceutical Chemicals Inc., Yousefabad, Jahanarar Avenue, Tehran, Iran.
Heli H; Nanomedicine and Nanobiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: hheli7@yahoo.com.

Int J Pharm ; 531(1): 299-305, 2017 Oct 05.

Article em En | MEDLINE | ID: mdl-28847671

Assuntos

Adenocarcinoma/tratamento farmacológico; Albuminas/química; Portadores de Fármacos/química; Cloridrato de Erlotinib/administração & dosagem; Nanopartículas/química; Neoplasias Pancreáticas/tratamento farmacológico; Linhagem Celular Tumoral; Humanos

Palavras-chave

Bovine serum albumin; Cytotoxicity; Erlotinib; Pancreatic cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Portadores de Fármacos / Adenocarcinoma / Albuminas / Nanopartículas / Cloridrato de Erlotinib Limite: Humans Idioma: En Revista: Int J Pharm Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google